The latest price target for Biolase (OTCQB:BIOL) was reported by Benchmark on August 12, 2024. The analyst firm set a price target for $0.40 expecting BIOL to rise to within 12 months (a possible 700.00% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Biolase (OTCQB:BIOL) was provided by Benchmark, and Biolase reiterated their speculative buy rating.

There is no last upgrade for Biolase

There is no last downgrade for Biolase.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biolase, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biolase was filed on August 12, 2024 so you should expect the next rating to be made available sometime around August 12, 2025.

While ratings are subjective and will change, the latest Biolase (BIOL) rating was a reiterated with a price target of $0.40 to $0.40. The current price Biolase (BIOL) is trading at is $0.05, which is out of the analyst’s predicted range.